Loading…
Ovarian cancer in BRCA-positive women: vigilance is mandatory despite screening programs
A young BRCA-1 positive woman turned out to have advanced stage ovarian cancer despite an ensuring check-up 4 months earlier. Much remains unknown regarding the efficacy of screening programs, when applied to individuals predisposed for an inherited malignancy. Therefore, vigilance is mandatory when...
Saved in:
| Published in: | European journal of obstetrics & gynecology and reproductive biology 2002-03, Vol.101 (2), p.196-198 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c391t-1cd4b67ba2ea373b6bb6a913caf402ce3c13ebca7bf2691b51b9c3feef3704663 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c391t-1cd4b67ba2ea373b6bb6a913caf402ce3c13ebca7bf2691b51b9c3feef3704663 |
| container_end_page | 198 |
| container_issue | 2 |
| container_start_page | 196 |
| container_title | European journal of obstetrics & gynecology and reproductive biology |
| container_volume | 101 |
| creator | Sloots, Karin Ausems, Margreet G.E.M. de Haan, Harm H. |
| description | A young BRCA-1 positive woman turned out to have advanced stage ovarian cancer despite an ensuring check-up 4 months earlier. Much remains unknown regarding the efficacy of screening programs, when applied to individuals predisposed for an inherited malignancy. Therefore, vigilance is mandatory when dealing with women with a positive family history of mammarian and/or ovarian cancer. |
| doi_str_mv | 10.1016/S0301-2115(01)00294-9 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71468999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0301211501002949</els_id><sourcerecordid>71468999</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-1cd4b67ba2ea373b6bb6a913caf402ce3c13ebca7bf2691b51b9c3feef3704663</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMoun78BCUXRQ_VTNOmjRfRxS9YEPwAbyFJp0tk265Jd2X_vVl30aPDwFyemXl5CDkEdg4MxMUL4wySFCA_ZXDGWCqzRG6QAZRFmhQizzbJ4BfZIbshfLBYnMttsgNQ5mUpywF5f5pr73RLrW4teupaevM8vE6mXXC9myP96hpsL-ncjd1kiVAXaKPbSvedX9AKw9T1SIP1iK1rx3Tqu7HXTdgnW7WeBDxYzz3ydnf7OnxIRk_3j8PrUWK5hD4BW2VGFEanqHnBjTBGaAnc6jpjqUVugaOxujB1KiSYHIy0vEasecEyIfgeOVndjY8_Zxh61bhgcRLDYjcLqoBMlFLKCOYr0PouBI-1mnrXaL9QwNRSqfpRqpa-VJw_StVy72j9YGYarP621g4jcLwGdLB6UvuoyYU_juex0zRyVysOo465Q6-CdRiVVs6j7VXVuX-ifANp6pPk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71468999</pqid></control><display><type>article</type><title>Ovarian cancer in BRCA-positive women: vigilance is mandatory despite screening programs</title><source>ScienceDirect Journals</source><creator>Sloots, Karin ; Ausems, Margreet G.E.M. ; de Haan, Harm H.</creator><creatorcontrib>Sloots, Karin ; Ausems, Margreet G.E.M. ; de Haan, Harm H.</creatorcontrib><description>A young BRCA-1 positive woman turned out to have advanced stage ovarian cancer despite an ensuring check-up 4 months earlier. Much remains unknown regarding the efficacy of screening programs, when applied to individuals predisposed for an inherited malignancy. Therefore, vigilance is mandatory when dealing with women with a positive family history of mammarian and/or ovarian cancer.</description><identifier>ISSN: 0301-2115</identifier><identifier>EISSN: 1872-7654</identifier><identifier>DOI: 10.1016/S0301-2115(01)00294-9</identifier><identifier>PMID: 11858898</identifier><identifier>CODEN: EOGRAL</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Adult ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; BRCA ; Case report ; Cisplatin - therapeutic use ; Female ; Genes, BRCA1 ; Gynecology. Andrology. Obstetrics ; Humans ; Hysterectomy ; Mammary gland diseases ; Mass Screening ; Medical sciences ; Mutation ; Ovarian malignancy ; Ovarian Neoplasms - diagnosis ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - therapy ; Paclitaxel - therapeutic use ; Tumors</subject><ispartof>European journal of obstetrics & gynecology and reproductive biology, 2002-03, Vol.101 (2), p.196-198</ispartof><rights>2002 Elsevier Science Ireland Ltd</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-1cd4b67ba2ea373b6bb6a913caf402ce3c13ebca7bf2691b51b9c3feef3704663</citedby><cites>FETCH-LOGICAL-c391t-1cd4b67ba2ea373b6bb6a913caf402ce3c13ebca7bf2691b51b9c3feef3704663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13513522$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11858898$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sloots, Karin</creatorcontrib><creatorcontrib>Ausems, Margreet G.E.M.</creatorcontrib><creatorcontrib>de Haan, Harm H.</creatorcontrib><title>Ovarian cancer in BRCA-positive women: vigilance is mandatory despite screening programs</title><title>European journal of obstetrics & gynecology and reproductive biology</title><addtitle>Eur J Obstet Gynecol Reprod Biol</addtitle><description>A young BRCA-1 positive woman turned out to have advanced stage ovarian cancer despite an ensuring check-up 4 months earlier. Much remains unknown regarding the efficacy of screening programs, when applied to individuals predisposed for an inherited malignancy. Therefore, vigilance is mandatory when dealing with women with a positive family history of mammarian and/or ovarian cancer.</description><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>BRCA</subject><subject>Case report</subject><subject>Cisplatin - therapeutic use</subject><subject>Female</subject><subject>Genes, BRCA1</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Hysterectomy</subject><subject>Mammary gland diseases</subject><subject>Mass Screening</subject><subject>Medical sciences</subject><subject>Mutation</subject><subject>Ovarian malignancy</subject><subject>Ovarian Neoplasms - diagnosis</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Paclitaxel - therapeutic use</subject><subject>Tumors</subject><issn>0301-2115</issn><issn>1872-7654</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqFkE1LxDAQhoMoun78BCUXRQ_VTNOmjRfRxS9YEPwAbyFJp0tk265Jd2X_vVl30aPDwFyemXl5CDkEdg4MxMUL4wySFCA_ZXDGWCqzRG6QAZRFmhQizzbJ4BfZIbshfLBYnMttsgNQ5mUpywF5f5pr73RLrW4teupaevM8vE6mXXC9myP96hpsL-ncjd1kiVAXaKPbSvedX9AKw9T1SIP1iK1rx3Tqu7HXTdgnW7WeBDxYzz3ydnf7OnxIRk_3j8PrUWK5hD4BW2VGFEanqHnBjTBGaAnc6jpjqUVugaOxujB1KiSYHIy0vEasecEyIfgeOVndjY8_Zxh61bhgcRLDYjcLqoBMlFLKCOYr0PouBI-1mnrXaL9QwNRSqfpRqpa-VJw_StVy72j9YGYarP621g4jcLwGdLB6UvuoyYU_juex0zRyVysOo465Q6-CdRiVVs6j7VXVuX-ifANp6pPk</recordid><startdate>20020310</startdate><enddate>20020310</enddate><creator>Sloots, Karin</creator><creator>Ausems, Margreet G.E.M.</creator><creator>de Haan, Harm H.</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020310</creationdate><title>Ovarian cancer in BRCA-positive women: vigilance is mandatory despite screening programs</title><author>Sloots, Karin ; Ausems, Margreet G.E.M. ; de Haan, Harm H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-1cd4b67ba2ea373b6bb6a913caf402ce3c13ebca7bf2691b51b9c3feef3704663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>BRCA</topic><topic>Case report</topic><topic>Cisplatin - therapeutic use</topic><topic>Female</topic><topic>Genes, BRCA1</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Hysterectomy</topic><topic>Mammary gland diseases</topic><topic>Mass Screening</topic><topic>Medical sciences</topic><topic>Mutation</topic><topic>Ovarian malignancy</topic><topic>Ovarian Neoplasms - diagnosis</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Paclitaxel - therapeutic use</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sloots, Karin</creatorcontrib><creatorcontrib>Ausems, Margreet G.E.M.</creatorcontrib><creatorcontrib>de Haan, Harm H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of obstetrics & gynecology and reproductive biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sloots, Karin</au><au>Ausems, Margreet G.E.M.</au><au>de Haan, Harm H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ovarian cancer in BRCA-positive women: vigilance is mandatory despite screening programs</atitle><jtitle>European journal of obstetrics & gynecology and reproductive biology</jtitle><addtitle>Eur J Obstet Gynecol Reprod Biol</addtitle><date>2002-03-10</date><risdate>2002</risdate><volume>101</volume><issue>2</issue><spage>196</spage><epage>198</epage><pages>196-198</pages><issn>0301-2115</issn><eissn>1872-7654</eissn><coden>EOGRAL</coden><notes>ObjectType-Case Study-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-4</notes><notes>content type line 23</notes><notes>ObjectType-Report-1</notes><notes>ObjectType-Article-3</notes><abstract>A young BRCA-1 positive woman turned out to have advanced stage ovarian cancer despite an ensuring check-up 4 months earlier. Much remains unknown regarding the efficacy of screening programs, when applied to individuals predisposed for an inherited malignancy. Therefore, vigilance is mandatory when dealing with women with a positive family history of mammarian and/or ovarian cancer.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>11858898</pmid><doi>10.1016/S0301-2115(01)00294-9</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-2115 |
| ispartof | European journal of obstetrics & gynecology and reproductive biology, 2002-03, Vol.101 (2), p.196-198 |
| issn | 0301-2115 1872-7654 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71468999 |
| source | ScienceDirect Journals |
| subjects | Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences BRCA Case report Cisplatin - therapeutic use Female Genes, BRCA1 Gynecology. Andrology. Obstetrics Humans Hysterectomy Mammary gland diseases Mass Screening Medical sciences Mutation Ovarian malignancy Ovarian Neoplasms - diagnosis Ovarian Neoplasms - pathology Ovarian Neoplasms - therapy Paclitaxel - therapeutic use Tumors |
| title | Ovarian cancer in BRCA-positive women: vigilance is mandatory despite screening programs |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T08%3A21%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ovarian%20cancer%20in%20BRCA-positive%20women:%20vigilance%20is%20mandatory%20despite%20screening%20programs&rft.jtitle=European%20journal%20of%20obstetrics%20&%20gynecology%20and%20reproductive%20biology&rft.au=Sloots,%20Karin&rft.date=2002-03-10&rft.volume=101&rft.issue=2&rft.spage=196&rft.epage=198&rft.pages=196-198&rft.issn=0301-2115&rft.eissn=1872-7654&rft.coden=EOGRAL&rft_id=info:doi/10.1016/S0301-2115(01)00294-9&rft_dat=%3Cproquest_cross%3E71468999%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c391t-1cd4b67ba2ea373b6bb6a913caf402ce3c13ebca7bf2691b51b9c3feef3704663%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71468999&rft_id=info:pmid/11858898&rfr_iscdi=true |